Bristol Myers Squibb Reports Positive Long-Term Phase 3 Data for Camzyos in Pediatric Patients
Bristol Myers Squibb (BMY) has released 56-week data from a Phase 3 clinical trial evaluating Camzyos (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in children aged 12 to 17. The study focused on patients receiving continuous dosing, providing critical long-term insights into the drug's efficacy and safety profile within this specific pediatric demographic. The results support the potential expansion of Camzyos' use cases, addressing an underserved patient population. As the company seeks regulatory pathways for pediatric indications, these data points are essential for demonstrating sustained clinical benefit and establishing a long-term safety baseline for younger patients.
Tickers: $BMY
Topics: clinical data pediatric cardiomyopathy Phase 3 trial